Changxia Shao
Overview
Explore the profile of Changxia Shao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shao C, Zhou H, Chen C, Dettman E, Ren Y, Cristescu R, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002171
Background/objectives: Mutations in and/or (BRCAm) and other homologous recombination repair genes (HRRm) are associated with several cancers. We evaluated the prevalence and association with overall survival (OS) of somatic BRCAm...
2.
Ma J, Groisberg R, Shao C, Zhong W
Sarcoma
. 2024 Nov;
2024:6735002.
PMID: 39502684
The classification of undifferentiated pleomorphic sarcoma (UPS) has been evolving with advances in immunohistochemistry and genomic profiling over the past 20 years. There is a lack of current information on...
3.
Liu X, Alipour G, Shao C, Burcu M, Bortnichak E, Vo T, et al.
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5851.
PMID: 39090803
Background: Oncology databases that integrate genomic and clinical data have become valuable resources for precision medicine. However, the generalizability of these databases has not been comprehensively assessed. Objectives: To describe...
4.
Chen C, Dettman E, Zhou W, Gozman A, Jin F, Lee L, et al.
Future Oncol
. 2024 Jul;
20(31):2357-2370.
PMID: 39011875
To determine the prevalence of deleterious mutations in and and in 13 genes involved in homologous recombination repair (HRR), the prevalence of genomic loss of heterozygosity and the allelic and...
5.
Zhong W, Ma J, Chen C, Dettman E, Cristescu R, Naik G, et al.
Cancer Med
. 2024 Jun;
13(11):e7358.
PMID: 38864477
Introduction: Hypoxia-inducible factor-2α (HIF-2α) modulates the hypoxic response pathway in tumors; however, mutations in pathways (including SDHA, SDHB, SDHC, SDHD, FH, and VHL genes) that are suspected to activate HIF-2α...
6.
Baek M, Chen L, Tekin C, Cristescu R, Jin X, Shao C, et al.
J Gynecol Oncol
. 2024 Jun;
35(6):e105.
PMID: 38857910
Objective: To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with non-immunotherapy-treated advanced cervical cancer. Methods: Clinical data...
7.
Shao C, Ren Y, Zhou H, Lee L, Chen C, Dettman E, et al.
Adv Ther
. 2024 Jan;
41(2):759-776.
PMID: 38169059
Introduction: Defects in the homologous recombination repair (HRR) pathway can include mutations in BRCA1 and BRCA2 (BRCAm) and other HRR genes (HRRm). These mutations are associated with a homologous recombination...
8.
Shui I, Burcu M, Shao C, Chen C, Liao C, Jiang S, et al.
Prostate Cancer Prostatic Dis
. 2023 Dec;
27(4):728-735.
PMID: 38057611
Background: Homologous recombination repair mutation (HRRm) status may guide risk-stratification and treatment decisions, including polyadenosine diphosphate-ribose polymerase inhibitor use, in advanced prostate cancer. Although HRRm prevalence has been reported in...
9.
Shao C, Ren Y, Zhou H, Chen C, Dettman E, Lee L, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300195.
PMID: 37972338
Purpose: Mutations in and/or (BRCAm), other homologous recombination repair genes (HRRm), and homologous recombination deficiency (HRD) lead to an accumulation of genomic alterations that can drive tumorigenesis. The prognostic impact...
10.
Wang C, Shao C, McDonald A, Amonkar M, Zhou W, Bortnichak E, et al.
JCO Clin Cancer Inform
. 2023 Jul;
7:e2200184.
PMID: 37437227
Purpose: Evaluating whether patient populations in clinico-genomic oncology databases are comparable with whom in other databases without genomic component is important. Methods: Four databases were compared for colorectal cancer (CRC)...